Chemotherapy plus two drugs for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a combination of chemotherapy with two additional drugs (nimotuzumab and toripalimab) for people with advanced nasopharyngeal cancer that hasn't been treated yet. The goal is to see if this mix works better than standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with advanced nasopharyngeal cancer (stage III or IVA, but not certain subtypes).
- You have not received any prior treatment for the tumor in your nose or neck (except a biopsy).
- Your general health is good enough to perform daily activities (ECOG score 0 or 1).
- Your organs and bone marrow are working well enough (doctor will check).
- You do not have other active cancers, serious infections, or autoimmune diseases that need treatment now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial tests if adding a PD-1 inhibitor to standard chemotherapy (TPF) before the main treatment can shrink advanced nasopharyngeal cancer that has spread beyond the nasopharynx. It is for people who have not had any prior treatment for their cancer.
This trial tests a combination of chemotherapy (GP), nimotuzumab, and sintilimab before standard treatment for locally advanced nasopharyngeal cancer. It aims to see if this approach can improve outcomes.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests a combination of two immune-based drugs (sintilimab and bevacizumab) plus standard chemotherapy for people with high-risk, locally advanced nasopharyngeal cancer that has spread to lymph nodes. The goal is to see if this approach works better than current treatments.
Hear when a new High Risk Locally Advanced Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.